Selank (Tuftsin Analogue)

What Is Selank? Sequence, Origin and Enkephalin Mechanism

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It combines tuftsin, an immunomodulatory tetrapeptide from immunoglobulin G, with a Pro-Gly-Pro extension that confers resistance to enzymatic degradation.

Key facts

Sequence
Thr-Lys-Pro-Arg-Pro-Gly-Pro
Single-letter
TKPRPGP
Length
7 residues (heptapeptide)
Molecular weight
751.9 Da
Molecular formula
C33H57N11O9
CAS number
129954-34-3
PubChem CID
11765600
Development code
TP-7
Western approval
None (not MHRA, EMA or FDA approved)

What it is built from

The Selank peptide has two parts. The first four residues, Thr-Lys-Pro-Arg, are tuftsin, a naturally occurring tetrapeptide released from the heavy chain of immunoglobulin G and long studied for immunomodulatory activity. The remaining three, Pro-Gly-Pro, are a stabilising extension. The design intent is to retain tuftsin's activity while giving it a useful duration in circulation.

Why the extension was necessary

Tuftsin on its own is degraded rapidly. Proline-containing motifs resist most peptidases, because proline's side chain bonds back to its own backbone nitrogen and locks the rotation that proteolytic enzymes need at their active site. Appending Pro-Gly-Pro therefore converts a fragile tetrapeptide into something that survives long enough to be studied. The same approach, from the same institute, produced Semax from an ACTH fragment.

Research material referenced

Selank 10mg, third-party HPLC tested

Buy Selank · £24.99

The mechanism that distinguishes it

The most specific reported activity is not receptor binding at all. Selank has been reported to inhibit enkephalin-degrading enzymes, extending the half-life of the body's own enkephalins rather than acting as an opioid ligand itself. Work from 2001 and 2002 in the Bulletin of Experimental Biology and Medicine measured this directly on plasma enkephalinase activity.

Other reported activity

Published work also describes effects on GABAergic signalling, on serotonergic and dopaminergic transmission, and on brain-derived neurotrophic factor expression. A 2008 study reported that intranasally administered Selank regulates BDNF expression in the rat hippocampus. As with Semax, the great majority of this is rodent work.

The evidence base, described accurately

PubMed indexes roughly 135 Selank records, a smaller literature than its parent peptide tuftsin, which has around 690. The mechanistic work appears in international journals; the clinical work is concentrated in Russian-language publications, principally the Korsakov Journal of Neurology and Psychiatry. That is a description of where the evidence sits, not a dismissal of it.

Regulatory position

Selank has a registration history in the Russian Federation. It holds no marketing authorisation from the MHRA, EMA or FDA, cannot be prescribed or dispensed in the UK, and is supplied here for laboratory research only. A registration granted by one national regulator confers nothing in any other jurisdiction.

Frequently asked questions

Is Selank approved in the UK?

No. It has a Russian registration history but holds no MHRA, EMA or FDA authorisation, and is supplied for laboratory research only.

What is Selank made from?

Tuftsin, a tetrapeptide from immunoglobulin G, with a Pro-Gly-Pro extension appended for stability.

Is Selank an opioid?

No. Reported work describes it slowing the breakdown of the body's own enkephalins by inhibiting enkephalin-degrading enzymes, rather than binding opioid receptors itself.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

Browse the wider literature

Live database searches, not fixed citations. Results change as new work is indexed.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More Selank (Tuftsin Analogue) articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.